IP Library Granted Patent US 12,497,651
Granted Patent B2
US 12,497,651 · App. 18/150,661 · Granted Dec 16, 2025

Encoded dual-probe endonuclease assays

Inventors: Jeffrey Brodin (San Diego, CA); Lorenzo Berti (San Diego, CA); Donald Brian Eidson (San Diego, CA); Christian Schlegel (San Diego, CA); Angela Blum (San Diego, CA); Rachel Schowalter (San Diego, CA); Ludovic Vincent (San Diego, CA); Pieter Van Rooyen (San Diego, CA); Gavin Stone (San Diego, CA); Hatim T. Allawi (Middleton, WI)
C12Q1/6827C12N9/22C12Q1/6874C12Q1/6886G16B30/20C12Q2600/154C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,497,651
App. No.
18/150,661
Granted
Dec 16, 2025
Kind
B2
Abstract

Methods are provided for conducting a dual-probe assay on a set of nucleic acid targets, including: combining a set of dual probes with a sample composition potentially comprising a set of nucleic acid targets to form a set of cleavable ternary nucleic acid complexes; releasing from the cleavable ternary nucleic acid complex a set of recognition element fragments; hybridizing each of the set of released recognition element fragments to a coded oligonucleotide probe and using resulting hybridized released recognition elements as primers for copying the coded oligonucleotide probe to produce a sect of target-associated codes, wherein each of the coded oligonucleotide probes comprises a code from a set of codes, each code comprises at least one segment encoding one or more symbols that correspond to a sequence of one or more nucleotides; and performing a detection event to identify a set of detected codes of the target-associated codes.

Claims (53)

1 . A method of conducting an assay for nucleic acid targets, the method comprising:

(a) combining dual probes with a sample composition potentially comprising nucleic acid targets to form cleavable ternary nucleic acid complexes, wherein:

(i) each of the dual probes comprise two probes;

(ii) a first probe of each of the dual probes comprises a first targeting sequence that is complementary to a first portion of a nucleic acid target;

(iii) a second probe of each of the dual probes comprises:

(1) a second targeting sequence; and

(2) a non-targeting recognition element sequence,

wherein the second targeting sequence is complementary to a second portion of the nucleic acid target and wherein the second targeting sequence of the second probe overlaps by at least one nucleotide with the first targeting sequence of the first probe;

(iv) binding of the dual probe to the nucleic acid target with no mismatches between the nucleic acid target and the second targeting sequence of the second probe at a nucleic acid target site of interest results in a cleavable ternary nucleic acid complex, wherein the cleavable ternary nucleic acid complex comprises the non-targeting recognition element sequence of the second probe;

(v) binding of the dual probe to a non-target nucleic acid with mismatches between the non-target nucleic acid and the second targeting sequence of the second probe results in an uncleavable ternary nucleic acid complex;

(b) releasing from the cleavable ternary nucleic acid complex the non-targeting recognition element sequence, thereby forming a recognition element fragment;

(c) hybridizing the released recognition element fragment to a coded oligonucleotide probe and using the resulting hybridized released recognition element fragment as a primer for copying the coded oligonucleotide probe to produce a set of target-associated codes, wherein the coded oligonucleotide probe comprises a code comprising at least one segment encoding one or more symbols that correspond to a sequence of one or more nucleotides; and

(d) performing a detection event to identify one or more detected codes of the target-associated codes;

wherein the one or more detected codes indicates the presence of the nucleic acid target in the sample composition.

2 . The method of claim 1 , further comprising, prior to performing the detection event, circularizing the coded oligonucleotide probe to produce a circular modified recognition element comprising the target-associated codes.

3 . The method of claim 2 , further comprising amplifying the circular modified recognition element, wherein the amplifying the circular modified recognition element comprises a rolling circle amplification reaction to yield a nucleic acid concatemer comprising multiple copies of the code.

4 . The method of claim 1 , further comprising amplifying the nucleic acid targets in parallel with:

(a) binding of the dual probe to the nucleic acid target and the non-target nucleic acid; and

(b) releasing the recognition element fragment.

5 . The method of claim 1 , wherein:

(a) each of the dual probes comprise from 3 to 100 coded recognition elements; and

(b) each of the coded recognition elements comprises a soft decodable code.

6 . The method of claim 1 , wherein:

(a) each of the dual probes comprises from 100 to 10,000 coded recognition elements; and

(b) each of the coded recognition elements comprises a soft decodable code.

7 . The method of claim 1 , wherein the performing the detection event comprises:

(a) recording a signal produced in response to an interrogation of each segment of each of the codes; and

(b) determining, upon completion of the interrogation, a probability of the presence of each of the codes by applying a soft-decision probabilistic decoding algorithm to the recorded signal.

8 . The method of claim 1 , wherein the performing the detection event comprises determining whether the code is present without determining a nucleic acid sequence of the code.

9 . The method of claim 1 , wherein the performing the detection event comprises determining whether the code is present without making a specific base call for each nucleotide in the code.

10 . The method of claim 1 , wherein the releasing comprises cleaving the ternary nucleic acid complex using a flap endonuclease.

11 . The method of claim 1 , wherein the first probe and the second probe of each of the dual probes:

(a) hybridize to one of the nucleic acid targets; and

(b) overlap at the nucleic acid target site of interest, leaving the non-targeting recognition element sequence unhybridized.

12 . The method of claim 1 , further comprising:

(a) counting the one or more detected codes to produce a code count for each detected code; and

(b) estimating nucleic acid target quantities based on the code count.

13 . The method of claim 1 , wherein the at least one segment encoding one or more symbols has a length ranging from 3 to 150 nucleotides.

14 . The method of claim 1 , wherein each code has a predetermined sequence.

15 . The method of claim 1 , wherein each code is selected to avoid interaction with other assay components.

16 . The method of claim 1 , wherein each of the dual probes or the coded oligonucleotide probes is unique for a specific nucleic acid target and comprises a code that is unique within a set of codes.

17 . The method of claim 1 , wherein each code is homopolymer free.

18 . The method of claim 1 , wherein each of the dual probes comprises one or more sample-specific barcodes.

19 . The method of claim 1 , wherein the sample composition comprises nucleic acids extracted from one or a combination of any of whole blood, lymphatic fluid, serum, plasma, sweat, tear, saliva, sputum, cerebrospinal fluid, amniotic fluid, seminal fluid, vaginal excretion, serous fluid, synovial fluid, pericardial fluid, peritoneal fluid, pleural fluid, transudates, exudates, cystic fluid, bile, urine, gastric fluid, intestinal fluid, fecal samples, liquids containing single or multiple cells, liquids containing organelles, fluidized tissues, fluidized organisms, liquids containing multi-celled organisms, biological swabs or biological washes.

20 . The method of claim 1 , wherein the nucleic acid targets comprise wild-type and/or mutated nucleic acid sequences.

21 . The method of claim 1 , wherein the nucleic acid targets comprise point mutations.

22 . The method of claim 1 , wherein the nucleic acid targets comprise substitutions, insertions and/or deletions.

23 . The method of claim 1 , wherein the nucleic acid targets comprise copy number variations.

24 . The method of claim 1 , wherein the nucleic acid targets comprise extracellular DNA fragments selected for methylation patterns indicative of cancer.

25 . The method of claim 24 , wherein the extracellular DNA fragments comprise bases, wherein the bases are transformed prior to the performing the detection event.

26 . The method of claim 1 , wherein the nucleic acid targets comprise methylated nucleotides.

27 . The method of claim 1 , wherein the nucleic acid targets comprise extracellular DNA fragments.

28 . The method of claim 1 , wherein the nucleic acid targets comprise RNA fragments.

Assignments (7)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT RIGHTS (REEL/FRAME 69898/0249) Recorded Mar 27, 2026
From: JPMORGAN CHASE BANK, N.A.
To: EXACT SCIENCES CORPORATION
Reel/Frame 075288/0393 →
PATENT SECURITY AGREEMENT Recorded Jan 14, 2025
From: EXACT SCIENCES CORPORATION
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 069898/0249 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 065782 FRAME 0385. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST. Recorded Dec 8, 2023
From: ALLAWI, HATIM T.
To: EXACT SCIENCES CORPORATION
Reel/Frame 065835/0042 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2023
From: ALLAWI, HATIM T.
To: EXACT SCIENCE CORPORATION
Reel/Frame 065782/0385 →
CORRECTIVE ASSIGNMENT TO CORRECT THE 3RD INVENTOR'S NAME PREVIOUSLY RECORDED ON REEL 062573 FRAME 0984. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST. Recorded Sep 14, 2023
From: BRODIN, JEFFREY; BERTI, LORENZO; EIDSON, DONALD BRIAN; SCHLEGEL, CHRISTIAN; BLUM, ANGELA; SCHOWALTER, RACHEL; VINCENT, LUDOVIC; VAN ROOYEN, PIETER; STONE, GAVIN
To: PLENO, INC.
Reel/Frame 064910/0707 →
CORRECTIVE ASSIGNMENT TO CORRECT THE LAST NAME OF INVENTOR PIETER VAN ROOYEN PREVIOUSLY RECORDED AT REEL: 062573 FRAME: 0984. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 17, 2023
From: BRODIN, JEFFREY; BERTI, LORENZO; EIDSON, BRIAN; SCHLEGEL, CHRISTIAN; BLUM, ANGELA; SCHOWALTER, RACHEL; VINCENT, LUDOVIC; VAN ROOYEN, PIETER; STONE, GAVIN
To: PLENO, INC.
Reel/Frame 062777/0366 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2023
From: BRODIN, JEFFREY; BERTI, LORENZO; EIDSON, BRIAN; SCHLEGEL, CHRISTIAN; BLUM, ANGELA; SCHOWALTER, RACHEL; VINCENT, LUDOVIC; ROOYEN, PIETER VAN; STONE, GAVIN
To: PLENO, INC.
Reel/Frame 062573/0984 →
Continuity (11)
Continuation PCTUS2022037791 · Jul 21, 2022
Continuation PCTUS2021060647 · Nov 23, 2021
Provisional Application 63346186 · May 26, 2022
Provisional Application 63317838 · Mar 8, 2022
Provisional Application 63234635 · Aug 18, 2021
Provisional Application 63222963 · Jul 17, 2021
Provisional Application 63183876 · May 4, 2021
Provisional Application 63157924 · Mar 8, 2021
Provisional Application 63126414 · Dec 16, 2020
Provisional Application 63116997 · Nov 23, 2020
Related Publication 20230257801A1 · Aug 17, 2023
References Cited (187)
US 5912124A · Kumar · 1999 [cited by applicant]
US 6221603B1 · Mahtani · 2001 [cited by applicant]
US 6225056B1 · Abe et al. · 2001 [cited by applicant]
US 6996475B2 · Balaban · 2006 [cited by applicant]
US 7074564B2 · Landegren · 2006 [cited by applicant]
US 7115364B1 · Chee et al. · 2006 [cited by applicant]
US 7189509B2 · Shao et al. · 2007 [cited by applicant]
US 7294466B2 · McMillan · 2007 [cited by applicant]
US 7427479B2 · Karger et al. · 2008 [cited by applicant]
US 8278052B2 · Lam et al. · 2012 [cited by applicant]
US 8407013B2 · Rogan · 2013 [cited by applicant]
US 8664164B2 · Ericsson et al. · 2014 [cited by applicant]
US 8828661B2 · Lucero et al. · 2014 [cited by applicant]
US 9090934B2 · Lucero et al. · 2015 [cited by applicant]
US 9234239B2 · Sikora et al. · 2016 [cited by applicant]
US 9624538B2 · Church et al. · 2017 [cited by applicant]
US 9809848B2 · Jones · 2017 [cited by applicant]
US 10093986B2 · Zhang et al. · 2018 [cited by applicant]
US 10108777B2 · Huang et al. · 2018 [cited by applicant]
US 10214773B2 · Jones · 2019 [cited by applicant]
US 10227632B2 · Jarvius · 2019 [cited by applicant]
US 10465245B2 · Mann et al. · 2019 [cited by applicant]
US 10513739B2 · Zhang et al. · 2019 [cited by applicant]
US 10731214B2 · Dahl et al. · 2020 [cited by applicant]
US 10829814B2 · Fan et al. · 2020 [cited by applicant]
US 10829821B2 · Zhang et al. · 2020 [cited by applicant]
US 10837879B2 · Burns et al. · 2020 [cited by applicant]
US 11028435B2 · Kelley et al. · 2021 [cited by applicant]
US 11549135B2 · Engreitz · 2023 [cited by applicant]
US 11597965B2 · Nilsson et al. · 2023 [cited by applicant]
US 11680284B2 · Gore et al. · 2023 [cited by applicant]
US 20040086892A1 · Crothers et al. · 2004 [cited by applicant]
US 20080269068A1 · Church et al. · 2008 [cited by applicant]
US 20110159499A1 · Hindson et al. · 2011 [cited by applicant]
US 20130084561A1 · Coull et al. · 2013 [cited by applicant]
US 20130109588A1 · Chun · 2013 [cited by examiner]
US 20130224729A1 · Church et al. · 2013 [cited by applicant]
US 20150004600A1 · Wang et al. · 2015 [cited by applicant]
US 20150284786A1 · Shapero et al. · 2015 [cited by applicant]
US 20150369772A1 · Van De Stolpe et al. · 2015 [cited by applicant]
US 20160010085A1 · Kwon et al. · 2016 [cited by applicant]
US 20160108460A1 · Lucero et al. · 2016 [cited by applicant]
US 20170183726A1 · Church et al. · 2017 [cited by applicant]
US 20180363039A1 · Weng et al. · 2018 [cited by applicant]
US 20190078150A1 · Chen et al. · 2019 [cited by applicant]
US 20190292581A1 · Egidio et al. · 2019 [cited by applicant]
US 20190309352A1 · Buis et al. · 2019 [cited by applicant]
US 20190352697A1 · Jones · 2019 [cited by applicant]
US 20200040376A1 · Russel et al. · 2020 [cited by applicant]
US 20200131570A1 · Berti et al. · 2020 [cited by applicant]
US 20200149037A1 · Shum · 2020 [cited by applicant]
US 20200224244A1 · Nilsson et al. · 2020 [cited by applicant]
US 20200255821A1 · Wang et al. · 2020 [cited by applicant]
US 20200277664A1 · Frenz · 2020 [cited by applicant]
US 20200309784A1 · Bertozzi et al. · 2020 [cited by applicant]
US 20210087625A1 · Fan et al. · 2021 [cited by applicant]
US 20210198727A1 · Kühnemund et al. · 2021 [cited by applicant]
US 20210238680A1 · Bava · 2021 [cited by applicant]
US 20210277460A1 · Bava · 2021 [cited by applicant]
US 20210340618A1 · Kühnemund et al. · 2021 [cited by applicant]
US 20210355483A1 · Chee et al. · 2021 [cited by applicant]
US 20220025429A1 · Liao et al. · 2022 [cited by applicant]
US 20220157400A1 · Struble et al. · 2022 [cited by applicant]
US 20220186301A1 · Nguyen et al. · 2022 [cited by applicant]
US 20220228200A1 · Bava · 2022 [cited by applicant]
US 20220358672A1 · Babadi et al. · 2022 [cited by applicant]
US 20220372654A1 · Fu et al. · 2022 [cited by applicant]
US 20220390442A1 · Luo et al. · 2022 [cited by applicant]
US 20220403457A1 · Glezer et al. · 2022 [cited by applicant]
US 20230021752A1 · Kapur et al. · 2023 [cited by applicant]
US 20230048356A1 · Zobeck et al. · 2023 [cited by applicant]
US 20230084407A1 · Hernández Neuta et al. · 2023 [cited by applicant]
US 20230115903A1 · Hernández Neuta et al. · 2023 [cited by applicant]
US 20230295739A1 · Brodin et al. · 2023 [cited by applicant]
EP 0867506A1 · 1998 [cited by applicant]
EP 1007725A1 · 2000 [cited by applicant]
EP 1141417A1 · 2001 [cited by applicant]
EP 1252334A2 · 2002 [cited by applicant]
EP 1297179B1 · 2008 [cited by applicant]
EP 1399588B1 · 2010 [cited by applicant]
EP 1558764B1 · 2011 [cited by applicant]
EP 2464753A1 · 2012 [cited by applicant]
EP 1423532B1 · 2013 [cited by applicant]
EP 2773452A1 · 2014 [cited by applicant]
EP 1745155B1 · 2014 [cited by applicant]
EP 2885638A2 · 2015 [cited by applicant]
EP 2954315A2 · 2015 [cited by applicant]
EP 2971121A1 · 2016 [cited by applicant]
EP 2456888B1 · 2016 [cited by applicant]
EP 3041957A1 · 2016 [cited by applicant]
EP 2504448B1 · 2016 [cited by applicant]
EP 2627781B1 · 2017 [cited by applicant]
EP 2236622B1 · 2017 [cited by applicant]
EP 3074535B1 · 2017 [cited by applicant]
EP 3383994A1 · 2018 [cited by applicant]
EP 3507364A1 · 2019 [cited by applicant]
EP 3541950A1 · 2019 [cited by applicant]
EP 3583214A1 · 2019 [cited by applicant]
EP 3126523B1 · 2020 [cited by applicant]
EP 3619326A1 · 2020 [cited by applicant]
EP 2885638B1 · 2020 [cited by applicant]
EP 3668998A1 · 2020 [cited by applicant]
EP 3696275A1 · 2020 [cited by applicant]
EP 3789490A1 · 2021 [cited by applicant]
EP 3798318A1 · 2021 [cited by applicant]
EP 3818177A1 · 2021 [cited by applicant]
EP 3555317B1 · 2021 [cited by applicant]
EP 3837365A1 · 2021 [cited by applicant]
EP 3770273B1 · 2021 [cited by applicant]
EP 3892735A1 · 2021 [cited by applicant]
EP 3918090A1 · 2021 [cited by applicant]
EP 3947721A1 · 2022 [cited by applicant]
EP 3976817A1 · 2022 [cited by applicant]
EP 4004234A1 · 2022 [cited by applicant]
EP 3872187B1 · 2022 [cited by applicant]
EP 4073270A1 · 2022 [cited by applicant]
WO WO9747769A1 · 1997 [cited by applicant]
WO WO9811210A1 · 1998 [cited by applicant]
WO WO9949079A1 · 1999 [cited by applicant]
WO WO0036141A1 · 2000 [cited by applicant]
WO WO0157256A2 · 2001 [cited by applicant]
WO WO2004044549A2 · 2004 [cited by applicant]
WO WO2005010199A2 · 2005 [cited by applicant]
WO WO2005061735A2 · 2005 [cited by applicant]
WO WO2007061284A1 · 2007 [cited by applicant]
WO WO2007120208A2 · 2007 [cited by applicant]
WO WO2011019874A1 · 2011 [cited by applicant]
WO WO2011066476A1 · 2011 [cited by applicant]
WO WO2012049316A1 · 2012 [cited by applicant]
WO WO2013066975A1 · 2013 [cited by applicant]
WO WO2013123220A1 · 2013 [cited by examiner]
WO WO2014122548A2 · 2014 [cited by applicant]
WO WO2014144371A1 · 2014 [cited by applicant]
WO WO2015035087A1 · 2015 [cited by applicant]
WO WO2015079042A1 · 2015 [cited by applicant]
WO WO2017087560A1 · 2017 [cited by applicant]
WO WO2017096322A1 · 2017 [cited by applicant]
WO WO2018094031A1 · 2018 [cited by applicant]
WO WO2018109206A1 · 2018 [cited by applicant]
WO WO2019068880A1 · 2019 [cited by applicant]
WO WO2019195268A2 · 2019 [cited by applicant]
WO WO2020069350A1 · 2020 [cited by applicant]
WO WO2020124050A1 · 2020 [cited by applicant]
WO WO2020193769A1 · 2020 [cited by applicant]
WO WO2020240025A1 · 2020 [cited by applicant]
WO WO2021007099A1 · 2021 [cited by applicant]
WO WO2021021982A1 · 2021 [cited by applicant]
WO WO2021033981A1 · 2021 [cited by applicant]
WO WO2021118435A1 · 2021 [cited by applicant]
WO WO2021123282A1 · 2021 [cited by applicant]
WO WO2021123286A1 · 2021 [cited by applicant]
WO WO2021146636A1 · 2021 [cited by applicant]
WO WO2022026891A1 · 2022 [cited by applicant]
WO WO2022040147A1 · 2022 [cited by applicant]
WO WO2022109496A2 · 2022 [cited by applicant]
WO WO2022159474A1 · 2022 [cited by applicant]
WO WO2022164989A2 · 2022 [cited by applicant]
WO WO2022197589A1 · 2022 [cited by applicant]
WO WO2022235764A1 · 2022 [cited by applicant]
WO WO2022236011A1 · 2022 [cited by applicant]
WO WO2022251586A1 · 2022 [cited by applicant]
WO WO2023015192A1 · 2023 [cited by applicant]
WO WO2023021518A1 · 2023 [cited by applicant]
WO WO2023077109A2 · 2023 [cited by applicant]
WO WO2023096671A1 · 2023 [cited by applicant]
WO WO2023096672A1 · 2023 [cited by applicant]
WO WO2023096674A1 · 2023 [cited by applicant]
WO WO2023096675A1 · 2023 [cited by applicant]
WO WO2023102245A1 · 2023 [cited by applicant]
WO WO2023122345A1 · 2023 [cited by applicant]
WO WO2023141588A1 · 2023 [cited by applicant]
WO WO2023158993A2 · 2023 [cited by applicant]
Ezpeleta, Joaquín, et al. “Designing robust watermark barcodes for multiplex long-read sequencing.” Bioinformatics 33.6 (2017): 807-813 (Year: 2017). [cited by examiner]
Ali, M. Monsur, et al. “Rolling circle amplification: a versatile tool for chemical biology, materials science and medicine.” Chemical Society Reviews 43.10 (2014): 3324-3341 (Year: 2014). [cited by examiner]
Frank, Daniel N. “BARCRAWL and BARTAB: software tools for the design and implementation of barcoded primers for highly multiplexed DNA sequencing.” BMC bioinformatics 10.1 (2009): 1-13 (Year: 2009). [cited by examiner]
Sun, Wei, et al. “The association between copy number aberration, DNA methylation and gene expression in tumor samples.” Nucleic acids research 46.6 (2018): 3009-3018 (Year: 2018). [cited by examiner]
Ong, Carmichael, et al. “Ligation with Nucleic Acid Sequence-Based Amplification.” The Journal of Molecular Diagnostics 14.3 (2012): 206-213 (Year: 2012). [cited by examiner]
Chen (Nucleic acids research 46.4 (2018): e22-e22) (Year: 2018). [cited by examiner]
Chung et al., Deterministic droplet-based co-encapsulation and pairing of microparticles via active sorting and downstream merging. Lab Chip. 17(21):3664-3671 (2017). [cited by applicant]
Lareau et al., Droplet-based combinatorial indexing for massive-scale single-cell chromatin accessibility. Nat Biotechnol. 916-924 (2019). [cited by applicant]
PCT/US2022/037791 International Search Report and Written Opinion dated Dec. 2, 2022. [cited by applicant]
Gao et al., Rolling circle amplification for single cell analysis and in situ sequencing. TrAC Trends in Analytical Chemistry. 121:115700, pp. (2019). [cited by applicant]
Sorvillo et al., Extracellular DNA NET-works with dire consequences for health. Circ Res. 125(4):470-488 (2019). [cited by applicant]
PCTUS2021060647 International Search Report and Written Opinion dated May 16, 2022. [cited by applicant]
PCTUS202237781 International Search Report and Written Opinion dated Dec. 19, 2022. [cited by applicant]
U.S. Appl. No. 18/150,669 Office Action dated Mar. 7, 2024. [cited by applicant]
U.S. Appl. No. 18/150,669 Office Action dated Sep. 5, 2024. [cited by applicant]